Pt Prodia Widyahusada Tbk · IDX:PRDA
Pt Prodia Widyahusada Tbk — FY2016 Earnings Presentation
30 slides from Pt Prodia Widyahusada Tbk's earnings presentation, Mar 20, 2017
Slide 1: PT Prodia Widyahusada Tbk 2016 Full Year Results Update
CONFIDENTIAL PT Prodia Widyahusada Tbk 2016 FULL YEAR RESULTS UPDATE 20 March 2017
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by PT Prodia Widyahusada (the "Company") solely for use in connection with the analyst presentation relating to the Company. The information contained in this presentation is strictly confidential and is provided to you solely for your reference. By vie
Slide 3: Agenda
confidential Agenda 1 INVESTMENT HIGHLIGHTS 2 2016 BUSINESS UPDATE 3 2017 GROWTH STRATEGIES 4 FINANCIAL HIGHLIGHTS 3
Slide 4: Investment Highlights
confidential 1 INVESTMENT HIGHLIGHTS 2 2016 BUSINESS UPDATE 3 2017 GROWTH STRATEGIES 4 FINANCIAL HIGHLIGHTS 4
Slide 5: Key Business Highlights
confidential Key Business Highlights Pd At the Forefront of a Significant Indonesian Healthcare Growth Opportunity Pioneer and Undisputed Market Leader in the Indonesian Independent Clinical Lab Industry
Slide 6: Prodia at the Forefront of a Significant Indonesian Healthcare Opportunity
1. Prodia is at the Forefront of a Significant Indonesian confidential Healthcare Opportunity Significant Long-term Growth Potential Total Indonesia Healthcare Expenditure (In USD bn) A Population of 256 million – 4th Largest Worldwide (3) Rapidly expanding middle class 29.0 25.4 26.5 27.6 Str
Slide 7: Significant Growth Potential for Private Laboratories in Indonesia
2. Significant Growth Potential for Private Laboratories inconfidential Indonesia Indonesian Healthcare Market is Growing Private Laboratory Testing Market is Growing Faster (Market size by revenue; In USD bn) (Market size by revenue; In USD mn) 13A-15E CAGR (0.3%) 817 29 28 27 27 26 706 25 24 615 5
Slide 8: confidential
confidential Source: Frost & Sullivan Analysis (2016).
Slide 9: Largest Owned and Operated Nationwide Labs Network
3. Largest Owned and Operated Nationwide Labs Network I II VII Clinical POC Hospital Clinical PHC POC Clinical POC Labs Outlet Lab Labs Clinic Outlet Labs Outlet Clinical Labs 129 and PHC 15 2 1 7 1 6 5 1 I VIII II Clinical POC Hospital Labs Outlet Lab 114 POC Outlets VII 12 15 1 VIII III V VI Clini
Slide 10: Scalable Hub and Spoke Model
© Scalable “Hub and Spoke” Model Qe? = Prodia Clinical Labs. " = Centralized e Hospital and Other Clinics reeled information with g Hub and spoke” model offers enema iain (PNRL) integrated IT platform scalable platform reducing that connects each lab to PNRL turnaround time and cost Q88 ; Spokes fac
Slide 11: Most-recognized Clinical Lab Brand in Indonesia
@® Most-recognized Clinical Lab Brand in Indonesia confidential ease” Drivers of Prodia’s Brand ™ The only clinical lab in Indonesia accredited by College of American Pathologists (“CAP”®)) ™ Received 56% of the votes from a sample of Indonesian consumers in the 2015 Top-Brand Survey ™ 15‘ clinical
Slide 12: Comprehensive Service Offering – Target Multiple Customer Segments
confidential 5. Comprehensive Service Offering – Target Multiple Customer Segments
Slide 13: Track Record of Growth with Improving Profitability
Track Record of Growth with Improving Profitability §“""°""',.& Revenue EBITDA') and EBITDA Margin (i IDR bn; %) {In IDR bn) 2013 2014 2015 2015H1 2016H1 2013 2014 2015 2015H1 2016H1
Slide 14: Senior Leadership and Management Team
confidential 7. Senior Leadership and Management Team Diagnostic Services Best Brand Gold Company of the Year 2015 2015 - Frost & Sullivan - IBBA Awards Drs. Gunawan Dr. Endang Scott Andrew Joseph Dr. Andi Prawiro Soeharto Hoyaranda Merrillees F. P, Luhukay Wijaya, MBA Co-Founder and Co-Founder and
Slide 15: 2016 Business Update
confidential 1 INVESTMENT HIGHLIGHTS 2 2016 BUSINESS UPDATE 3 2017 GROWTH STRATEGIES 4 FINANCIAL HIGHLIGHTS 15
Slide 16: 2016 Outlets Development
confidential 2016 Outlets Development Clinical Labs Point-of-Care (POC) Specialty Clinics Hospital Labs & PHCs Outlets Equipped to conduct Specialized facilities and process certain Consists of both POC focusing on particular Operate hospital labs routine tests Centers and POC fields of medicine
Slide 17: 2016 Most Recognized Clinical Lab Brand for Prodia
2016 MOST RECOGNIZED Clinical Lab Brand for Prodia confidential Top Brand Award Indonesia Original Brand (IOB ) Indonesia Best Brand Award (IBBA) Corporate Image Award (IMAC) 2009 - 2016 2012 - 2016 2013 - 2016 2012 - 2016 Service Quality Award 2013,2015 - 2016 2015- 2016 2012 - 2016 Master Service
Slide 18: 2016 Full Year Results
confidential 2016 FULL YEAR RESULTS Financial 2016 Revenue (IDR Bn) 1,358.66 ▲ 13.44% EBITDA (IDR Bn) 209.07 ▲ 19.31% EBITDA Margin 15.38% ▲ 76 bps Net Income (IDR Bn) 88.13 ▲ 49.32% • No of visits (mn) 2.48 ▲ 4.19% • Revenue per visit (IDR 000) 547 ▲ 8.89% • New Testing Types 11 New Outlets 2016 Cl
Slide 19: 2017 Growth Strategies
confidential 1 INVESTMENT HIGHLIGHT 2 2016 BUSINESS UPDATE 3 2017 GROWTH STRATEGIES 4 FINANCIAL HIGHLIGHT 21
Slide 20: Growth Strategies
confidential Growth Strategies A Near-term 1 Expand our presence and grow our network of outlets in both existing and new markets in Indonesia 2 Upgrade existing clinical laboratories to provide wider range of tests and services and increase volume 3 Enhance internal operating efficiency 4 Focus on
Slide 21: Near-Term Growth Plan
confidential Near-Term Growth Plan Prodia’s Network Expansion Plan in Five Years 1 2 Expand Network of Outlets Upgrade Clinical Labs Upgrade up to 39 additional clinical labs to 4 regional reference labs(1) PHC Clinics(3) Up to 33 additional clinical labs over next five years 24 Clinical Lab Improve
Slide 22: Leader in Next Generation Technology
Leader in Next Generation Technology confidential (Long-term Strategy) Immunology Laboratory Platforms Molecular Diagnostics (Flow Cytometry) Lab Innovation Diversified Clinical Diagnostics Platform + Scientific Talent Chromatography-Mass Advanced Pathology Lab Spectrometry The Concept of Precision
Slide 23: Financial Highlights
confidential 1 INVESTMENT HIGHLIGHTS 2 2016 BUSINESS UPDATE 3 2017 GROWTH STRATEGIES 4 FINANCIAL HIGHLIGHTS 25
Slide 24: Revenue and EBITDA increased more than average growth over previous three years
confidential Revenue and EBITDA increased more than average growth over previous three years Revenue EBITDA In IDR bn In IDR bn 1,358 209 1,198 175 1,081 986 148 132 15.4% 14.6% 13.4% 13.7% 2013 2014 2015 2016 2013 2014 2015 2016 2016 Revenue increase by 13.44% driven by external referral (15.16%)
Slide 25: Improving Gross Profit and Net Income
confidential Improving Gross Profit and Net Income Gross Profit Net Income In IDR bn In IDR bn Gross Profit Net Income 793 88 59 687 2015 2016 2015 2016 The improvement of Gross Profit is driven by reducing of direct cost of raw materials
Slide 26: Cost Structure
confidential Cost Structure Cost of Revenues Key Commentary (In IDR bn) Cost of revenues decreased 42.7% 42.0% 41.6% due to reduction of direct costs 565 511 from 35.8 % to 35% driven 454 90 384 82 72 by a reduction of cost of raw 47 337 475 382 429 materials 38.9% 2013A 2014A 2015A 2016 FY Colu
Slide 27: Capital Expenditure
confidential Capital Expenditure Capital Expenditure Highlights (In IDR bn) Capital expenditure generally 321.8 relates to the costs associated with opening new clinical laboratories Capital expenditure in 2016 273.3 was more due to the cost of renovation, and ERP-Sispro 26.9% 77.2 XSIS software
Slide 28: Equity and Assets Ratio
confidential Equity and Assets Ratio 2016 2015 Debt to Assets Equity Ratio (DAR) 0.31 0.78 ▼ Debt to Equity Ratio (DER) 0.44 3.57 ▼ Return On Assets (ROA) 3.81 11.51 ▼ Return On Equity (ROE) 5.48 52.64 ▼
Slide 29: Share Holder
Share Holder confidential No.1 clinical lab chain in Indonesia(1) Premium clinical laboratory brand Dominant and industry pioneer PT. PRODIA WIDYAHUSADA TBK Nationwide Outlet Network across Indonesia PT. Prodia Utama Bio Majesty Pte. Ltd Public 57% 18% 25.0% Note: (1) By revenue and lab networ
Slide 30: Thank You
SG Li Rid for Quality THANKYOU